全文获取类型
收费全文 | 31849篇 |
免费 | 1654篇 |
国内免费 | 92篇 |
专业分类
耳鼻咽喉 | 690篇 |
儿科学 | 1274篇 |
妇产科学 | 513篇 |
基础医学 | 3637篇 |
口腔科学 | 671篇 |
临床医学 | 2090篇 |
内科学 | 8626篇 |
皮肤病学 | 1146篇 |
神经病学 | 2085篇 |
特种医学 | 772篇 |
外科学 | 4693篇 |
综合类 | 159篇 |
一般理论 | 8篇 |
预防医学 | 2564篇 |
眼科学 | 864篇 |
药学 | 1811篇 |
1篇 | |
中国医学 | 112篇 |
肿瘤学 | 1879篇 |
出版年
2023年 | 192篇 |
2022年 | 159篇 |
2021年 | 734篇 |
2020年 | 323篇 |
2019年 | 821篇 |
2018年 | 1183篇 |
2017年 | 721篇 |
2016年 | 626篇 |
2015年 | 695篇 |
2014年 | 783篇 |
2013年 | 1220篇 |
2012年 | 2146篇 |
2011年 | 2306篇 |
2010年 | 1255篇 |
2009年 | 927篇 |
2008年 | 1889篇 |
2007年 | 2103篇 |
2006年 | 1903篇 |
2005年 | 1958篇 |
2004年 | 1787篇 |
2003年 | 1748篇 |
2002年 | 1658篇 |
2001年 | 1105篇 |
2000年 | 1369篇 |
1999年 | 1022篇 |
1998年 | 170篇 |
1997年 | 115篇 |
1996年 | 140篇 |
1995年 | 82篇 |
1994年 | 73篇 |
1993年 | 65篇 |
1992年 | 343篇 |
1991年 | 260篇 |
1990年 | 210篇 |
1989年 | 158篇 |
1988年 | 167篇 |
1987年 | 166篇 |
1986年 | 129篇 |
1985年 | 125篇 |
1984年 | 98篇 |
1983年 | 71篇 |
1981年 | 46篇 |
1980年 | 32篇 |
1979年 | 57篇 |
1976年 | 41篇 |
1974年 | 35篇 |
1973年 | 36篇 |
1972年 | 31篇 |
1971年 | 30篇 |
1968年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
3.
Maria Gonzalez-Cao Cristina Carrera Juan Francisco Rodriguez Moreno Pedro Rodríguez-Jiménez Mónica Antoñanzas Basa Rosa Feltes Ochoa Teresa Puertolas Eva Muñoz-Couselo José Luis Manzano Ivan Marquez-Rodas Juan Martín-Liberal Ainara Soria Pilar Lopez Criado Almudena Garcia-Castaño Aram Boada Pablo Ayala de Miguel Susana Puig Guillermo Crespo Alfonso Berrocal 《Journal of the American Academy of Dermatology》2021,84(5):1412-1415
4.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
5.
Hagop Kantarjian Tapan Kadia Courtney DiNardo Naval Daver Gautam Borthakur Elias Jabbour Guillermo Garcia-Manero Marina Konopleva Farhad Ravandi 《Blood cancer journal》2021,11(2)
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.Subject terms: Prognosis, Health services 相似文献
6.
7.
8.
José A. Lorente Pablo Cardinal-Fernández Diego Muñoz Fernando Frutos-Vivar Arnaud W. Thille Carlos Jaramillo Aida Ballén-Barragán José M. Rodríguez Oscar Peñuelas Guillermo Ortiz José Blanco Bruno Valle Pinheiro Nicolás Nin María del Carmen Marin Andrés Esteban Taylor B. Thompson 《Intensive care medicine》2015,41(11):1921-1930
9.
Miguel A. Sanz Pau Montesinos Haesook T. Kim Guillermo J. Ruiz-Argüelles María S. Undurraga María R. Uriarte Lem Martínez Rafael H. Jacomo Homero Gutiérrez-Aguirre Raul A. M. Melo Rosane Bittencourt Ricardo Pasquini Katia Pagnano Evandro M. Fagundes Edo Vellenga Alexandra Holowiecka Ana J. González-Huerta Pascual Fernández Javier De la Serna Salut Brunet Elena De Lisa José González-Campos José M. Ribera Isabel Krsnik Arnold Ganser Nancy Berliner Raul C. Ribeiro Francesco Lo-Coco Bob L?wenberg Eduardo M. Rego 《Annals of hematology》2015,94(8):1347-1356
10.